Search Results - "GHABRI, Salah"

Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial by Priotto, Gerardo, Dr, Kasparian, Serena, MD, Mutombo, Wilfried, MD, Ngouama, Daniel, MD, Ghorashian, Sara, MD, Arnold, Ute, MD, Ghabri, Salah, PhD, Baudin, Elisabeth, MD, Buard, Vincent, MD, Kazadi-Kyanza, Serge, MD, Ilunga, Médard, MD, Mutangala, Willy, MD, Pohlig, Gabriele, PhD, Schmid, Caecilia, PhD, Karunakara, Unni, PhD, Torreele, Els, PhD, Kande, Victor, MD

“…Summary Background Human African trypanosomiasis (HAT; sleeping sickness) caused by Trypanosoma brucei gambiense is a fatal disease. Current treatment options…”
Get full text

Could or Should We Use Cost-Effectiveness Thresholds in the French Value-Based Pricing Process for New Drugs? by Ghabri, Salah

“…In general, there are five regulatory/pricing approaches (including or excluding VBP): (1) an approach based on comparing health gains to cost-effectiveness…”
Get full text

In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness by Schmid, Caecilia, Kuemmerle, Andrea, Blum, Johannes, Ghabri, Salah, Kande, Victor, Mutombo, Wilfried, Ilunga, Medard, Lumpungu, Ismael, Mutanda, Sylvain, Nganzobo, Pathou, Tete, Digas, Mubwa, Nono, Kisala, Mays, Blesson, Severine, Mordt, Olaf Valverde

“…Trypanosoma brucei (T.b.) gambiense Human African trypanosomiasis (HAT; sleeping sickness) is a fatal disease. Until 2009, available treatments for 2(nd) stage…”
Get full text

Emerging Good Practices for Quantitative Benefit-Risk Assessment: A Step Forward by Ghabri, Salah

Get full text

Methods for Including Adverse Events in Economic Evaluations: Suggestions for Improvement by Ghabri, Salah, Dawoud, Dalia, Drummond, Michael

“…Inclusion of relevant effectiveness and safety outcomes in economic evaluation of health technologies is required to aid efficient healthcare decisions. Our…”
Get full text

The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges by Ghabri, Salah, Mauskopf, Josephine

Get full text

Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda by Guerin, Philippe J, Naess, Lisbeth M, Fogg, Carole, Rosenqvist, Einar, Pinoges, Loretxu, Bajunirwe, Francis, Nabasumba, Carolyn, Borrow, Ray, Frøholm, Leif O, Ghabri, Salah, Batwala, Vincent, Twesigye, Rogers, Aaberge, Ingeborg S, Røttingen, John-Arne, Piola, Patrice, Caugant, Dominique A

“…Neisseria meningitidis serogroup A is the main causative pathogen of meningitis epidemics in sub-Saharan Africa. In recent years, serogroup W135 has also been…”
Get full text

Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling by Corro Ramos, Isaac, Feenstra, Talitha, Ghabri, Salah, Al, Maiwenn

“…[...]some publications include a sensitivity analysis as part of model validation [22, 23], although a sensitivity analysis aims to explore uncertainty, not…”
Get full text

Four Aspects Affecting Health Economic Decision Models and Their Validation by Feenstra, Talitha, Corro-Ramos, Isaac, Hamerlijnck, Dominique, van Voorn, George, Ghabri, Salah

“…Health care decision makers in many jurisdictions use cost-effectiveness analysis based on health economic decision models for policy decisions regarding…”
Get full text

Towards a New Framework for Addressing Structural Uncertainty in Health Technology Assessment Guidelines by Ghabri, Salah, Cleemput, Irina, Josselin, Jean-Michel

“…Published online: 20 December 2017 © Springer International Publishing AG, part of Springer Nature 2017 1Introduction Providing scientific advice and…”
Get full text

Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force by Fenwick, Elisabeth, Steuten, Lotte, Knies, Saskia, Ghabri, Salah, Basu, Anirban, Murray, James F., Koffijberg, Hendrik (Erik), Strong, Mark, Sanders Schmidler, Gillian D., Rothery, Claire

“…Healthcare resource allocation decisions made under conditions of uncertainty may turn out to be suboptimal. In a resource constrained system in which there is…”
Get full text

Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic Drugs by Ghabri, Salah, Lam, Laurent, Bocquet, François, Spath, Hans-Martin

“…Objective This systematic literature review (SLR) had two objectives: to analyse published economic evaluations of biological disease-modifying anti-rheumatic…”
Get full text

Critical Appraisal of Systematic Reviews With Costs and Cost-Effectiveness Outcomes: An ISPOR Good Practices Task Force Report by Mandrik, Olena (Lena), Severens, J.L. (Hans), Bardach, Ariel, Ghabri, Salah, Hamel, Candyce, Mathes, Tim, Vale, Luke, Wisløff, Torbjørn, Goldhaber-Fiebert, Jeremy D.

“…A systematic review (SR) can provide rigorous and complete evidence to support decision makers who consider both the effectiveness and cost-effectiveness of…”
Get full text

Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force by Rothery, Claire, Strong, Mark, Koffijberg, Hendrik (Erik), Basu, Anirban, Ghabri, Salah, Knies, Saskia, Murray, James F., Sanders Schmidler, Gillian D., Steuten, Lotte, Fenwick, Elisabeth

“…The allocation of healthcare resources among competing priorities requires an assessment of the expected costs and health effects of investing resources in the…”
Get full text

Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France by Ghabri, Salah, Binard, Aymeric, Pers, Yves-Marie, Maunoury, Franck, Caro, J. Jaime

“…Biologic disease-modifying antirheumatic drugs (bDMARDs) are prescribed sequentially in the treatment of rheumatoid arthritis (RA). Healthcare decision makers…”
Get full text

Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic Drugs by Ghabri, Salah, Lam, Laurent, Bocquet, François, Spath, Hans-Martin

“…Objective This systematic literature review (SLR) had two objectives: to analyse published economic evaluations of biological disease-modifying anti-rheumatic…”
Get full text

Trusting the Results of Model-Based Economic Analyses: Is there a Pragmatic Validation Solution? by Ghabri, Salah, Stevenson, Matt, Möller, Jörgen, Caro, J. Jaime

“…Models have become a nearly essential component of health technology assessment. This is because the efficacy and safety data available from clinical trials…”
Get full text

Could or Should We Use MCDA in the French HTA Process? by Ghabri, Salah, Josselin, Jean-Michel, Le Maux, Benoît

“…Reimbursement is based on clinical benefit as assessed by the Transparency Committee (CT) for drugs and the Medical Device and Health Technology Evaluation…”
Get full text

The French National Authority for Health by Ghabri, Salah, Autin, Erwan, Poullié, Anne-Isabelle, Josselin, Jean Michel

“…Background Budget impact analysis (BIA) provides short- and medium-term estimates on changes in budgets and health outcomes resulting from the adoption of new…”
Get full text

Recommendations on the Use of Structured Expert Elicitation Protocols for Healthcare Decision Making: A Good Practices Report of an ISPOR Task Force by Soares, Marta, Colson, Abigail, Bojke, Laura, Ghabri, Salah, Garay, Osvaldo Ulises, Felli, Jenna K., Lee, Karen, Molsen-David, Elizabeth, Morales-Napoles, Oswaldo, Shaffer, Victoria A., IJzerman, Maarten J.

“…Healthcare decision making, including regulatory and reimbursement decisions, is based on uncertain assessments of clinical and economic value. This arises…”
Get full text